Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 5Phase 3 3Phase NA 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Breast Neoplasms 26Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Prostatic Neoplasms 8Multiple Myeloma 7Lung Neoplasms 7Melanoma 6Stomach Neoplasms 5Leukemia, Myeloid, Acute 5Glioma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Tuberous Sclerosis 3Sarcoma 3Papillomavirus Infections 3Neoplasm Metastasis 3Hematologic Neoplasms 3Glioblastoma 3Warts 2Venous Thromboembolism 2Thyroid Neoplasms 2Skin Neoplasms 2Rectal Neoplasms 2Polycythemia Vera 2Pain 2Ovarian Neoplasms 2Oligodendroglioma 2Obesity 2Neoplasms by Site 2Myasthenia Gravis 2

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Gastrointestinal Stromal Tumors × 90 days × Clear all
NCT01742299 2026-05-14

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Novartis

Phase 4 Completed
155 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡